A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
AUTHORS
Shou
YYaping ,
Robinson
DM Douglas M ,
Amakye
DD Dereck D ,
Rose
KL Kristine L ,
Cho
YJ Yoon-Jae ,
Ligon
KL Keith L ,
Sharp
T Thad ,
Haider
AS Asifa S ,
Bandaru
R Raj ,
Ando
Y Yuichi ,
Geoerger
B Birgit ,
Doz
F François ,
Ashley
DM David M ,
Hargrave
DR Darren R ,
Casanova
M Michela ,
Tawbi
HA Hussein A ,
Rodon
J Jordi ,
Thomas
AL Anne L ,
Mita
AC Alain C ,
MacDonald
TJ Tobey J ,
Kieran
MW Mark W .
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 2 1; 21(3).
585-93
ABSTRACT
Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pathway-activated medulloblastoma.
Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pathway-activated medulloblastoma.